Real-time PCR, Digital PCR, And End-point PCR Market Size
| Study Period | 2020 - 2030 |
| Market Size (2025) | USD 8.03 Billion |
| Market Size (2030) | USD 9.75 Billion |
| CAGR (2025 - 2030) | 3.98% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players*Disclaimer: Major Players sorted in no particular order |
Real-time PCR, Digital PCR, And End-point PCR Market Analysis
The Real-time PCR, Digital PCR, And End-point PCR Market size is estimated at USD 8.03 billion in 2025, and is expected to reach USD 9.75 billion by 2030, at a CAGR of 3.98% during the forecast period (2025-2030).
Major factors, such as the introduction of novel technologies in PCR systems and the increasing prevalence of infectious diseases, chronic conditions, and genetic disorders, are anticipated to significantly drive the growth of the Real-Time PCR, Digital PCR, and End-Point PCR markets.
The global rise in infectious diseases is intensifying the demand for diagnostic tools that deliver rapid and accurate results. For instance, a report published by the World Health Organization in December 2024 revealed an increase in global malaria cases from 252 million in 2022 to 263 million in 2023. This notable rise underscores the critical need for advanced diagnostic solutions to ensure timely and precise malaria detection. The growing burden of malaria is expected to boost the adoption of real-time PCR, digital PCR, and end-point PCR technologies. These methods, recognized for their high sensitivity and specificity in pathogen detection, are instrumental in enhancing disease management and control strategies.
Similarly, a study published in the Cureus Journal in February 2024 highlighted that in India, hemophilia A affects approximately one in every 1,000 individuals, accounting for 70% of hemophilia cases. In India, the prevalence of hemophilia is estimated at 0.7 cases per lakh population, equating to around 54,454 diagnosed cases. In contrast, hemophilia B in India is significantly less prevalent at 0.1 per 100,000 individuals, compared to 1.3 per 100,000 in the United States. The increasing prevalence of hemophilia emphasizes the urgent need for advanced diagnostic tools to facilitate accurate detection and monitoring. This rising demand is projected to drive the adoption of real-time PCR, digital PCR, and endpoint PCR technologies, which provide precision and reliability in identifying genetic mutations associated with such conditions, thereby supporting market growth.
Furthermore, ongoing technological advancements are expected to further propel the growth of the real-time PCR, digital PCR, and endpoint PCR markets. For instance, in November 2023, Roche introduced the LightCycler PRO System, an advanced qPCR technology developed on the established LightCycler platform. This system offers enhanced performance and usability for both clinical diagnostics and research applications. By bridging translational research and in-vitro diagnostics, while complementing a robust molecular PCR testing portfolio, this innovation is anticipated to accelerate market growth. The introduction of advanced PCR technologies with enhanced performance and usability, bridging research and clinical diagnostics, is driving the growth of real-time PCR, digital PCR, and endpoint PCR markets by improving testing efficiency and broadening application possibilities in molecular diagnostics.
However, the high cost associated with PCR devices remains a significant challenge, potentially restraining the growth of the real-time PCR, digital PCR, and endpoint PCR markets.
Real-time PCR, Digital PCR, And End-point PCR Market Trends
Clinical Diagnostics Segment is Expected to Witness a Significant Growth Over the Forecast Period
Real-time PCR, digital PCR, and end-point PCR have significantly advanced molecular diagnostics by delivering exceptional sensitivity, specificity, and quantitative precision. These state-of-the-art technologies are integral to clinical applications, particularly in the diagnosis of infectious diseases, genetic disorders, and cancer. Key drivers such as the increasing prevalence of infectious diseases, progress in personalized medicine, and continuous technological innovations are anticipated to propel the growth of the clinical diagnostics segment within the market.
The growing prevalence of infectious diseases has substantially increased the demand for advanced diagnostic tools. The emergence of novel pathogens has accelerated the adoption of PCR-based assays, recognized for their proven accuracy in detecting and quantifying these threats. For instance, a report published by the World Health Organization in October 2024 revealed that in 2023, tuberculosis (TB) affected over 10.8 million individuals globally, including 6.0 million men, 3.6 million women, and 1.3 million children. This data highlights the widespread impact of TB across all demographics. The WHO Southeast Asia Region accounted for 45% of new cases, followed by the African Region at 24% and the Western Pacific Region at 17%. Furthermore, 87% of cases were concentrated in 30 high-burden countries, including Bangladesh, China, and India.
The rising global burden of TB, particularly in high-prevalence regions, underscores the critical need for advanced diagnostic technologies such as real-time PCR, digital PCR, and endpoint PCR, which enable rapid and precise detection. This growing demand for efficient diagnostic solutions is expected to drive substantial growth in the clinical diagnostics segment of the PCR market. Additionally, the global challenge of antimicrobial resistance further emphasizes the importance of rapid and accurate pathogen identification. PCR-based techniques play a pivotal role in facilitating timely and effective treatment strategies.
Technological advancements have significantly enhanced the capabilities and efficiency of PCR-based applications. The miniaturization and automation of PCR systems have improved accessibility, particularly in point-of-care settings, by streamlining workflows and enhancing operational efficiency. For instance, in August 2023, Gold Standard Diagnostics introduced its DNAllergen real-time PCR kits. This innovation represents a major advancement in allergen testing by employing molecular methods to detect allergens that are difficult to identify using traditional immunoassays. This approach enhances diagnostic precision and reliability in allergen detection, positioning the launch to drive growth in the clinical diagnostics segment of the real-time PCR, digital PCR, and endpoint PCR market by addressing the increasing demand for advanced molecular diagnostic solutions.
Similarly, in February 2023, Thermo Fisher Scientific launched its real-time PCR kits in India for the detection of infectious diseases, emphasizing accuracy and reliability in diagnostic applications. These kits, which have received regulatory approval for local manufacturing, strengthen diagnostic capabilities in the region. This development is expected to contribute to the growth of the clinical diagnostics segment across the real-time PCR, digital PCR, and endpoint PCR markets by improving accessibility and advancing precision in disease detection.
In conclusion, the integration of innovative PCR-based technologies, combined with the increasing global burden of infectious diseases and advancements in point-of-care diagnostics, is projected to drive significant growth in the clinical diagnostics segment.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
The North American region is anticipated to hold a substantial share of the real-time PCR, digital PCR, and endpoint PCR markets. This growth is attributed to factors such as the increasing prevalence of chronic diseases, expanding R&D initiatives, and frequent product launches, all of which are expected to drive the development of these markets in North America.
For instance, according to a report released in February 2024 by CA: A Cancer Journal for Clinicians forecasted 2,001,140 new cancer cases in the United States for the year 2024. This projection highlights the growing cancer burden and the critical need for advanced diagnostic solutions to address the rising incidence of various cancer types. The increasing prevalence of breast, prostate, pancreatic, and HPV-associated cancers, along with persistent disparities in cancer mortality among specific populations, underscores the demand for precise diagnostic tools and equitable healthcare access. These factors are accelerating the adoption of innovative technologies that enable early and accurate cancer detection, thereby driving the growth of the real-time PCR, digital PCR, and endpoint PCR markets.
Similarly, a report published by the Canadian Cancer Society in May 2024 emphasizes the rising incidence of cancer in Canada, with an estimated 127,100 males and 120,000 females expected to be diagnosed in 2024. The significant prevalence of prostate cancer among males (22% of cases) and breast cancer among females (25% of cases), coupled with the alarming diagnosis rates of lung cancer in females (17,300 cases) and males (14,800 cases), highlights the growing need for advanced and rapid cancer detection technologies. These developments are driving the adoption of cutting-edge molecular diagnostic tools to support early detection, accurate diagnosis, and personalized treatment planning in oncology.
Moreover, the increasing number of product launches in the region is expected to further propel market growth during the forecast period. For instance, in February 2023, Co-Diagnostics, Inc. initiated clinical evaluations for its Co-Dx PCR Home platform, which includes clinical trials and analytical studies aimed at regulatory submissions. This innovation facilitates real-time molecular diagnostic testing in at-home and point-of-care settings. Such advancements are expected to significantly contribute to the growth of the real-time PCR, digital PCR, and endpoint PCR markets by enhancing accessibility and expanding applications in infectious disease detection.
In conclusion, the rising prevalence of chronic diseases, expanding R&D activities, and increasing product innovations are key drivers of growth in the real-time PCR, digital PCR, and endpoint PCR markets in North America, particularly in the areas of oncology and infectious disease detection.
Real-time PCR, Digital PCR, And End-point PCR Industry Overview
The real-time PCR, digital PCR, and endpoint PCR market is moderately consolidated due to a few large companies. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Abbott, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, and Thermo Fisher Scientific Inc., among others.
Real-time PCR, Digital PCR, And End-point PCR Market Leaders
-
Abbott
-
Bio-Rad Laboratories, Inc.
-
F. Hoffmann-La Roche Ltd.
-
Merck KGaA
-
Thermo Fisher Scientific Inc.
- *Disclaimer: Major Players sorted in no particular order
Real-time PCR, Digital PCR, And End-point PCR Market News
- September 2024: QIAGEN N.V. launched its QIAcuityDx Digital PCR System, expanding its digital PCR portfolio into clinical diagnostics. The system is 510(k) exempt in the United States and IVDR-certified for diagnostic use in Europe.
- April 2024: Bio-Rad Laboratories, Inc. launched its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ESR1 Mutation Detection Kit. This new assay expands the company’s Droplet Digital PCR (ddPCR) offering for the oncology market.
Real-time PCR, Digital PCR, And End-point PCR Industry Segmentation
Real-time PCR enables the monitoring of DNA amplification in real-time, delivering both quantitative and qualitative insights. In contrast, digital PCR offers absolute quantification by partitioning samples into numerous individual reactions, while end-point PCR focuses on detecting DNA amplification at the reaction's conclusion, providing qualitative results.
The real-time PCR, digital PCR, and endpoint PCR market is segmented by product, technology, application, and geography. The product segment is further divided into instruments, reagents, consumables, and others. The technology segment is further segmented into real-time PCR, digital PCR, and end-point PCR. The real-time PCR is further divided into Quantitative PCR and Reverse Transcription PCR. The digital PCR is further segmented into Droplet Digital PCR (ddPCR), and Chip-Based Digital PCR. The application segment is further divided into clinical diagnostics, research and development, and others. The geography segment is further segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report offers the value (in USD) for the above segments.
| By Product | Instruments | ||
| Reagents and Consumables | |||
| Others | |||
| By Technology | Real-Time PCR (qPCR) | Quantitative PCR | |
| Reverse Transcription PCR | |||
| Digital PCR (dPCR) | Droplet Digital PCR (ddPCR) | ||
| Chip-Based Digital PCR | |||
| End-Point PCR | |||
| By Application | Clinical Diagnostics | ||
| Research and Development | |||
| Others | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle-East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle-East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Real-time PCR, Digital PCR, And End-point PCR Market Research FAQs
How big is the Real-time PCR, Digital PCR, And End-point PCR Market?
The Real-time PCR, Digital PCR, And End-point PCR Market size is expected to reach USD 8.03 billion in 2025 and grow at a CAGR of 3.98% to reach USD 9.75 billion by 2030.
What is the current Real-time PCR, Digital PCR, And End-point PCR Market size?
In 2025, the Real-time PCR, Digital PCR, And End-point PCR Market size is expected to reach USD 8.03 billion.
Who are the key players in Real-time PCR, Digital PCR, And End-point PCR Market?
Abbott, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Merck KGaA and Thermo Fisher Scientific Inc. are the major companies operating in the Real-time PCR, Digital PCR, And End-point PCR Market.
Which is the fastest growing region in Real-time PCR, Digital PCR, And End-point PCR Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Real-time PCR, Digital PCR, And End-point PCR Market?
In 2025, the North America accounts for the largest market share in Real-time PCR, Digital PCR, And End-point PCR Market.
What years does this Real-time PCR, Digital PCR, And End-point PCR Market cover, and what was the market size in 2024?
In 2024, the Real-time PCR, Digital PCR, And End-point PCR Market size was estimated at USD 7.71 billion. The report covers the Real-time PCR, Digital PCR, And End-point PCR Market historical market size for years: 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Real-time PCR, Digital PCR, And End-point PCR Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
